Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.

NCT Number	NCT07358715
Lead Sponsor	National University Hospital, Singapore Collaborators: Gene Solutions
Conditions	Lung Cancer, Lung Neoplasms, Early Lung Cancer Detection, Cancer Screening, High-Risk Populations
Enrollment	140 participants
Start Date	2024-11-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-22